- All sections
- A - Human necessities
- A61P - Specific therapeutic activity of chemical compounds or medicinal preparations
- A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
Patent holdings for IPC class A61P 1/16
Total number of patents in this class: 7441
10-year publication summary
|
239
|
290
|
512
|
603
|
721
|
837
|
922
|
783
|
627
|
12
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Novartis AG | 11297 |
67 |
| Genfit | 265 |
57 |
| Gilead Sciences, Inc. | 1949 |
57 |
| Daiichi Sankyo Company, Limited | 1863 |
55 |
| Takeda Pharmaceutical Company Limited | 2945 |
48 |
| Sunshine Lake Pharma Co., Ltd. | 567 |
48 |
| Albireo AB | 163 |
43 |
| Osaka University | 3288 |
43 |
| Eli Lilly and Company | 3718 |
41 |
| Bristol-myers Squibb Company | 4886 |
39 |
| The Regents of the University of California | 19479 |
39 |
| InterCept Pharmaceuticals, Inc. | 218 |
34 |
| Pfizer Inc. | 3373 |
33 |
| Kowa Company, Ltd. | 1193 |
32 |
| Chugai Seiyaku Kabushiki Kaisha | 1315 |
29 |
| Regeneron Pharmaceuticals, Inc. | 3974 |
29 |
| Boehringer Ingelheim International GmbH | 4762 |
27 |
| The University of Tokyo | 4051 |
27 |
| China Pharmaceutical University | 268 |
26 |
| Inserm (institut National de La Sante et de La Recherche Medicale) | 3353 |
26 |
| Other owners | 6641 |